Quantum Genomics
Focus: Quantum Genomics is a Paris-based biotechnology company focused on small-molecule therapeutics in neurology and respiratory indications. The company operates a hybrid model combining generic/ANDA products with early-stage pipeline programs in cardiovascular disease.
Profile data last refreshed 17h ago · AI intelligence enriched 1w ago
Open Jobs
0
About Quantum Genomics
AI assessmentNot HiringNo open roles listed right now. Follow Quantum Genomics to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from Quantum Genomics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Data completeness
2/9 — Limited
Company HealthStrong
Pipeline
Mid-stage
2 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Key Products
Pre-Launch
ANDA benzodiazepine generating the bulk of current revenue (54% concentration) but pre-launch status and aging MOA class indicate limited growth potential.
Help build intelligence for Quantum Genomics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.